Your browser doesn't support javascript.
loading
A phase 1/2 study of carfilzomib in Japanese patients with relapsed and/or refractory multiple myeloma.
Watanabe, Takashi; Tobinai, Kensei; Matsumoto, Morio; Suzuki, Kenshi; Sunami, Kazutaka; Ishida, Tadao; Ando, Kiyoshi; Chou, Takaaki; Ozaki, Shuji; Taniwaki, Masafumi; Uike, Naokuni; Shibayama, Hirohiko; Hatake, Kiyohiko; Izutsu, Koji; Ishikawa, Takayuki; Shumiya, Yoshihisa; Kashihara, Tomohisa; Iida, Shinsuke.
  • Watanabe T; Department of Haematology, National Cancer Centre Hospital, Tokyo, Japan.
  • Tobinai K; Department of Haematology, Komaki City Hospital, Komaki, Japan.
  • Matsumoto M; Department of Haematology, National Cancer Centre Hospital, Tokyo, Japan.
  • Suzuki K; Department of Haematology, National Hospital Organization Nishigunma National Hospital, Shibukawa, Japan.
  • Sunami K; Department of Haematology, Japanese Red Cross Medical Centre, Tokyo, Japan.
  • Ishida T; Department of Haematology, National Hospital Organization Okayama Medical Centre, Okayama, Japan.
  • Ando K; Department of Gastroenterology, Rheumatology and Clinical Immunology, Sapporo Medical University School of Medicine, Sapporo, Japan.
  • Chou T; Department of Haematology and Oncology, Tokai University School of Medicine, Isehara, Japan.
  • Ozaki S; Department of Internal Medicine, Niigata Cancer Centre Hospital, Niigata, Japan.
  • Taniwaki M; Department of Haematology, Tokushima Prefectural Central Hospital, Tokushima, Japan.
  • Uike N; Division of Haematology and Oncology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
  • Shibayama H; Department of Haematology, National Hospital Organization Kyushu Cancer Centre, Fukuoka, Japan.
  • Hatake K; Department of Haematology and Oncology, Osaka University Graduate School of Medicine, Suita, Japan.
  • Izutsu K; Department of Haematology and Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Ishikawa T; Department of Haematology, Toranomon Hospital, Tokyo, Japan.
  • Shumiya Y; Department of Haematology, Kobe City Medical Centre General Hospital, Kobe, Japan.
  • Kashihara T; Department of Oncology Clinical Development Planning, Ono Pharmaceutical Co., Ltd., Osaka, Japan.
  • Iida S; Department of Oncology Clinical Development Planning, Ono Pharmaceutical Co., Ltd., Osaka, Japan.
Br J Haematol ; 172(5): 745-56, 2016 Mar.
Article en En | MEDLINE | ID: mdl-26732066
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Oligopéptidos / Mieloma Múltiple / Antineoplásicos Tipo de estudio: Clinical_trials Límite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Año: 2016 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Oligopéptidos / Mieloma Múltiple / Antineoplásicos Tipo de estudio: Clinical_trials Límite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Año: 2016 Tipo del documento: Article